{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:11:42Z","timestamp":1780546302725,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Clinical practice guidelines recommend the use of all approved granulocyte colony-stimulating factors (G-CSFs), including filgrastim and pegfilgrastim, as primary febrile neutropenia (FN) prophylaxis in patients receiving high- or intermediate-risk regimens (in those with additional patient risk factors). Previous studies have examined G-CSF cost-effectiveness by cancer type in patients with a high baseline risk of FN.<\/jats:p>\n                <jats:p>This study evaluated patients with breast cancer (BC), non-small cell lung cancer (NSCLC), or non-Hodgkin\u2019s lymphoma (NHL) receiving therapy who were at intermediate risk for FN and compared primary prophylaxis (PP) and secondary prophylaxis (SP) using biosimilar filgrastim or biosimilar pegfilgrastim in Austria, France, and Germany.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A Markov cycle tree-based model was constructed to evaluate PP versus SP in patients with BC, NSCLC, or NHL receiving therapy over a lifetime horizon. Cost-effectiveness was evaluated over a range of willingness-to-pay (WTP) thresholds for incremental cost per quality-adjusted life year (QALY) gained. Sensitivity analyses evaluated uncertainty.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Results demonstrated that using biosimilar filgrastim as PP compared to SP resulted in incremental cost-effectiveness ratios (ICERs) well below the most commonly accepted WTP threshold of \u20ac30,000. Across all three countries, PP in NSCLC had the lowest cost per QALY, and in France, PP was both cheaper and more effective than SP. Similar results were found using biosimilar pegfilgrastim, with ICERs generally higher than those for filgrastim.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Biosimilar filgrastim and pegfilgrastim as primary prophylaxis are cost-effective approaches to avoid FN events in patients with BC, NSCLC, or NHL at intermediate risk for FN in Austria, France, and Germany.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-023-08043-4","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T07:01:46Z","timestamp":1695193306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Matti S.","family":"Aapro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Chaplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cornes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Koptelova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Di Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridgette Kanz","family":"Schroader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Terkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"issue":"12","key":"8043_CR1","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMct1210890","volume":"368","author":"CL Bennett","year":"2013","unstructured":"Bennett CL, Djulbegovic B, Norris LB, Armitage JO (2013) Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 368(12):1131\u20131139","journal-title":"N Engl J Med"},{"issue":"2","key":"8043_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/cam4.200","volume":"3","author":"E Culakova","year":"2014","unstructured":"Culakova E, Thota R, Poniewierski MS, Kuderer NM, Wogu AF, Dale DC et al (2014) Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med 3(2):434\u2013444","journal-title":"Cancer Med"},{"issue":"10","key":"8043_CR3","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258\u20132266","journal-title":"Cancer"},{"key":"8043_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/1472-6963-14-189","volume":"14","author":"D Weycker","year":"2014","unstructured":"Weycker D, Barron R, Edelsberg J, Kartashov A, Legg J, Glass AG (2014) Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC Health Serv Res 14:189","journal-title":"BMC Health Serv Res"},{"issue":"10","key":"8043_CR5","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24(10):2475\u20132484","journal-title":"Ann Oncol"},{"issue":"6","key":"8043_CR6","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","volume":"13","author":"E Tai","year":"2017","unstructured":"Tai E, Guy GP, Dunbar A, Richardson LC (2017) Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012. J Oncol Pract 13(6):e552\u2013ee61","journal-title":"J Oncol Pract"},{"issue":"9","key":"8043_CR7","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1093\/annonc\/mdy311","volume":"29","author":"GH Lyman","year":"2018","unstructured":"Lyman GH, Yau L, Nakov R, Krendyukov A (2018) Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann Oncol 29(9):1903\u20131910","journal-title":"Ann Oncol"},{"issue":"13","key":"8043_CR8","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2217\/fon-2018-0762","volume":"15","author":"P Cornes","year":"2019","unstructured":"Cornes P, Krendyukov A (2019) The evolution of value with filgrastim in oncology. Future Oncol 15(13):1525\u20131533","journal-title":"Future Oncol"},{"issue":"11","key":"8043_CR9","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1007\/s12325-018-0798-6","volume":"35","author":"P Cornes","year":"2018","unstructured":"Cornes P, Gascon P, Chan S, Hameed K, Mitchell CR, Field P et al (2018) Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia. Adv Ther 35(11):1816\u20131829","journal-title":"Adv Ther"},{"issue":"3","key":"8043_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40259-020-00411-4","volume":"34","author":"P Cornes","year":"2020","unstructured":"Cornes P, Gascon P, Vulto AG, Aapro M (2020) Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure. BioDrugs. 34(3):255\u2013263","journal-title":"BioDrugs."},{"issue":"suppl 5","key":"8043_CR11","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M et al (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27(suppl 5):v111\u2013v1v8","journal-title":"Ann Oncol"},{"issue":"4","key":"8043_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40273-016-0474-0","volume":"35","author":"K Fust","year":"2017","unstructured":"Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R et al (2017) Cost-effectiveness analysis of prophylaxis treatment strategies to reduce the incidence of febrile neutropenia in patients with early-stage breast cancer or non-Hodgkin lymphoma. Pharmacoeconomics 35(4):425\u2013438","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"8043_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3111\/13696998.2013.844160","volume":"17","author":"G Hill","year":"2014","unstructured":"Hill G, Barron R, Fust K, Skornicki ME, Taylor DC, Weinstein MC et al (2014) Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin\u2019s lymphoma: cost-effectiveness analyses. J Med Econ 17(1):32\u201342","journal-title":"J Med Econ"},{"issue":"2","key":"8043_CR14","doi-asserted-by":"publisher","first-page":"e0148901","DOI":"10.1371\/journal.pone.0148901","volume":"11","author":"XJ Wang","year":"2016","unstructured":"Wang XJ, Tang T, Farid M, Quek R, Tao M, Lim ST et al (2016) Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy. PLoS One 11(2):e0148901","journal-title":"PLoS One"},{"issue":"8","key":"8043_CR15","doi-asserted-by":"publisher","first-page":"e1235","DOI":"10.1200\/OP.20.01047","volume":"17","author":"E Li","year":"2021","unstructured":"Li E, Mezzio DJ, Campbell D, Campbell K, Lyman GH (2021) Primary prophylaxis with biosimilar filgrastim for patients at intermediate risk for febrile neutropenia: a cost-effectiveness analysis. JCO Oncol Pract 17(8):e1235\u2013e1e45","journal-title":"JCO Oncol Pract"},{"key":"8043_CR16","volume-title":"European Parliament Directorate general for research working paper","author":"SACO","year":"2002","unstructured":"SACO (2002) Health care systems in the Eu a comparative study. In: European Parliament Directorate general for research working paper.\u00a0https:\/\/www.europarl.europa.eu\/workingpapers\/saco\/pdf\/101_en.pdf. Accessed 3 Dec 2021"},{"issue":"11","key":"8043_CR17","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1182\/blood.V104.11.2210.2210","volume":"104","author":"JWD Crawford","year":"2004","unstructured":"Crawford JWD (2004) First cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: results from a prospective nationwide study. Blood 104(11):2210","journal-title":"Blood"},{"issue":"3","key":"8043_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10549-018-4935-3","volume":"172","author":"SA Narod","year":"2018","unstructured":"Narod SA, Giannakeas V, Sopik V (2018) Time to death in breast cancer patients as an indicator of treatment response. Breast Cancer Res Treat 172(3):659\u2013669","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"8043_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0959-8049(02)00486-0","volume":"39","author":"R Taylor","year":"2003","unstructured":"Taylor R, Davis P, Boyages J (2003) Long-term survival of women with breast cancer in New South Wales. Eur J Cancer 39(2):215\u2013222","journal-title":"Eur J Cancer"},{"issue":"1","key":"8043_CR20","doi-asserted-by":"publisher","first-page":"1717030","DOI":"10.1080\/20016689.2020.1717030","volume":"8","author":"JA McDougall","year":"2020","unstructured":"McDougall JA, Furnback WE, Wang BCM, Mahlich J (2020) Understanding the global measurement of willingness to pay in health. J Mark Access Health Policy 8(1):1717030","journal-title":"J Mark Access Health Policy"},{"issue":"11","key":"8043_CR21","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","volume":"23","author":"L Wang","year":"2015","unstructured":"Wang L, Baser O, Kutikova L, Page JH, Barron R (2015) The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 23(11):3131\u20133140","journal-title":"Support Care Cancer"},{"issue":"31","key":"8043_CR22","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1200\/JCO.2007.12.6094","volume":"26","author":"A Bezjak","year":"2008","unstructured":"Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B et al (2008) Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol 26(31):5052\u20135059","journal-title":"J Clin Oncol"},{"issue":"3","key":"8043_CR23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-019-05171-6","volume":"175","author":"RJA Camara","year":"2019","unstructured":"Camara RJA, Schwentner L, Friedl TWP, Deniz M, Fink V, Lato K et al (2019) Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial. Breast Cancer Res Treat 175(3):627\u2013635","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"8043_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jval.2010.10.037","volume":"14","author":"S Whyte","year":"2011","unstructured":"Whyte S, Cooper KL, Stevenson MD, Madan J, Akehurst R (2011) Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. Value Health 14(4):465\u2013474","journal-title":"Value Health"},{"key":"8043_CR25","unstructured":"European Medicines Agency (2023) Medicines search. https:\/\/www.ema.europa.eu\/en\/medicines. Accessed 1 May 2022"},{"issue":"1","key":"8043_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6004\/jnccn.2020.0002","volume":"18","author":"PS Becker","year":"2020","unstructured":"Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R et al (2020) NCCN Guidelines insights: hematopoietic growth factors, Version 1.2020. J Natl Compr Cancer Netw 18(1):12\u201322","journal-title":"J Natl Compr Cancer Netw"},{"issue":"28","key":"8043_CR27","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199\u20133212","journal-title":"J Clin Oncol"},{"issue":"19","key":"8043_CR28","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 24(19):3187\u20133205","journal-title":"J Clin Oncol."},{"issue":"1","key":"8043_CR29","doi-asserted-by":"publisher","first-page":"100038","DOI":"10.1016\/j.esmoop.2020.100038","volume":"6","author":"M Aapro","year":"2021","unstructured":"Aapro M, Lyman GH, Bokemeyer C, Rapoport BL, Mathieson N, Koptelova N et al (2021) Supportive care in patients with cancer during the COVID-19 pandemic. ESMO Open 6(1):100038","journal-title":"ESMO Open"},{"key":"8043_CR30","unstructured":"IQVIA (2021) The impact of biosimilar competition in Europe 2020. https:\/\/www.iqvia.com\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe. Accessed 3 Dec 2021"},{"key":"8043_CR31","unstructured":"Amgen (2021) Biosimilar Trends Report, 8th ed. https:\/\/www.amgenbiosimilars.com\/-\/media\/Themes\/Amgen\/amgenbiosimilars-com\/Amgenbiosimilars-com\/pdf\/USA-CBU-80961_Amgen-Biosimilars-Trend-Report.pdf. Accessed 3 Dec 2021"},{"key":"8043_CR32","unstructured":"IQVIA (2021) The impact of biosimilar competition in Europe. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe-2021.pdf?_=1640100592119. Accessed 3 Dec 2021"},{"issue":"4","key":"8043_CR33","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00520-018-4481-x","volume":"27","author":"H Link","year":"2019","unstructured":"Link H, Kerkmann M, Holtmann L, Ortner P (2019) G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey. Support Care Cancer 27(4):1459\u20131469","journal-title":"Support Care Cancer"},{"issue":"1","key":"8043_CR34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00520-015-2779-5","volume":"24","author":"H Link","year":"2016","unstructured":"Link H, Nietsch J, Kerkmann M, Ortner P (2016) Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany. Support Care Cancer 24(1):367\u2013376","journal-title":"Support Care Cancer"},{"issue":"2","key":"8043_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40259-019-00395-w","volume":"34","author":"B Dutta","year":"2020","unstructured":"Dutta B, Huys I, Vulto AG, Simoens S (2020) Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs 34(2):159\u2013170","journal-title":"BioDrugs."},{"issue":"5","key":"8043_CR36","doi-asserted-by":"publisher","first-page":"e0216835","DOI":"10.1371\/journal.pone.0216835","volume":"14","author":"CW Baugh","year":"2019","unstructured":"Baugh CW, Faridi MK, Mueller EL, Camargo CA Jr, Pallin DJ (2019) Near-universal hospitalization of US emergency department patients with cancer and febrile neutropenia. PLoS One 14(5):e0216835","journal-title":"PLoS One"},{"issue":"8","key":"8043_CR37","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M (2022) Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed? Oncologist. 27(8):625\u2013636","journal-title":"Oncologist."},{"issue":"12","key":"8043_CR38","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41416-021-01690-6","volume":"126","author":"A de Gregorio","year":"2022","unstructured":"de Gregorio A, Janni W, Friedl TWP, Nitz U, Rack B, Schneeweiss A et al (2022) The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. Br J Cancer 126(12):1715\u20131724","journal-title":"Br J Cancer"},{"issue":"3","key":"8043_CR39","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10549-015-3531-z","volume":"153","author":"T Do","year":"2015","unstructured":"Do T, Medhekar R, Bhat R, Chen H, Niravath P, Trivedi MV (2015) The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis. Breast Cancer Res Treat 153(3):591\u2013597","journal-title":"Breast Cancer Res Treat"},{"key":"8043_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.breast.2021.03.012","volume":"58","author":"M Clemons","year":"2021","unstructured":"Clemons M, Fergusson D, Joy AA, Thavorn K, Meza-Junco J, Hiller JP et al (2021) A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. Breast 58:42\u201349","journal-title":"Breast"},{"issue":"16","key":"8043_CR41","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663\u20131671","journal-title":"N Engl J Med"},{"issue":"3","key":"8043_CR42","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jemermed.2019.09.032","volume":"58","author":"W Marshall","year":"2020","unstructured":"Marshall W, Campbell G, Knight T, Al-Sayed T, Cooksley T (2020) Emergency ambulatory management of low-risk febrile neutropenia: multinational association for supportive care in cancer fits-real-world experience from a UK Cancer Center. J Emerg Med 58(3):444\u2013448","journal-title":"J Emerg Med"},{"issue":"3","key":"8043_CR43","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00520-017-3921-3","volume":"26","author":"BW Teh","year":"2018","unstructured":"Teh BW, Brown C, Joyce T, Worth LJ, Slavin MA, Thursky KA (2018) Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre. Support Care Cancer 26(3):997\u20131003","journal-title":"Support Care Cancer"},{"key":"8043_CR44","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.ctrv.2022.102427","volume":"109","author":"DW Blayney","year":"2022","unstructured":"Blayney DW, Schwartzberg L (2022) Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review. Cancer Treat Rev 109:102427","journal-title":"Cancer Treat Rev"},{"key":"8043_CR45","unstructured":"Sandoz GmbH (2013) Zarzio SmPC. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zarzio-epar-product-information_en.pdf. Accessed 3 Dec 2021"},{"key":"8043_CR46","unstructured":"Sandoz GmbH (2018) Ziextenzo SmPC. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ziextenzo-epar-product-information_en.pdf. Accessed 3 Dec 2021"},{"key":"8043_CR47","doi-asserted-by":"publisher","first-page":"103193","DOI":"10.1016\/j.critrevonc.2020.103193","volume":"157","author":"P Lapidari","year":"2021","unstructured":"Lapidari P, Vaz-Luis I, Di Meglio A (2021) Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: a systematic review. Crit Rev Oncol Hematol 157:103193","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08043-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08043-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08043-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:08:22Z","timestamp":1697533702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08043-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["8043"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08043-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"assertion":[{"value":"30 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was required for this work as it did not involve patient-specific information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"SC and BKS are employees of Xcenda. SH, AM, and NK are employees of Sandoz. RT and MA have no competing interests to disclose. HL reports financial interests via advisory board involvement in the following: Apogepha, G1 Therapeutics, Hogg Robinson Germany, Lindis Blood Care, Pharmacosmos, Servier Deutschland GmbH, SIGAL SMS GmbH, Takeda, and Teva; expert testimony for Samsung Bioepis and Ethics Committee at the Rhineland-Palatinate Medical Association; invited speaker for Teva and Vision Plus Mailand; and ownership interest, research grants, licencing fees, coordinating PI, and steering committee member for Onkodin GmbH, AMGEN and Pharmacosmos, Viatris, and Teva-Xcenda, respectively. PC declares honoraria or support for attending meetings from Accord Healthcare, Amgen, Astro Pharma, European Association for Hospital Pharmacists, European Commission, Medicines for Europe\/European Generics Association, Medscape, Mylan, Napp, Pfizer\/Hospira, Sandoz, Teva and Viatris. MP reports clinical research projects with Bayer, Sandoz, Pierre Fabre, Fresenius, Astellas, Janssen, and Sanofi; Speakers\u2019 bureau with Amgen, KyowaKirin, MSD, and Mundipharma; Honoraria from Novartis and AstraZeneca; travel and accommodations and expenses from Pfizer and Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"581"}}